Last reviewed · How we verify
NDec - oral decitabine-tetrahydrouridine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
NDec - oral decitabine-tetrahydrouridine (NDec - oral decitabine-tetrahydrouridine) — Novo Nordisk A/S.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NDec - oral decitabine-tetrahydrouridine TARGET | NDec - oral decitabine-tetrahydrouridine | Novo Nordisk A/S | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NDec - oral decitabine-tetrahydrouridine CI watch — RSS
- NDec - oral decitabine-tetrahydrouridine CI watch — Atom
- NDec - oral decitabine-tetrahydrouridine CI watch — JSON
- NDec - oral decitabine-tetrahydrouridine alone — RSS
Cite this brief
Drug Landscape (2026). NDec - oral decitabine-tetrahydrouridine — Competitive Intelligence Brief. https://druglandscape.com/ci/ndec-oral-decitabine-tetrahydrouridine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab